Boston Scientific Corporation
BSX · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.27 | 0.37 | -2.69 | -0.06 |
| FCF Yield | 2.01% | 2.03% | 1.38% | 2.18% |
| EV / EBITDA | 36.10 | 26.82 | 27.20 | 26.98 |
| Quality | ||||
| ROIC | 6.13% | 5.69% | 3.89% | 6.58% |
| Gross Margin | 61.31% | 62.02% | 60.83% | 62.76% |
| Cash Conversion Ratio | 1.86 | 1.57 | 2.19 | 1.80 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.71% | 6.20% | 8.56% | 3.46% |
| Free Cash Flow Growth | 55.31% | 86.32% | -30.55% | 16.25% |
| Safety | ||||
| Net Debt / EBITDA | 2.73 | 2.50 | 3.05 | 2.99 |
| Interest Coverage | 6.81 | 8.02 | 3.93 | 5.51 |
| Efficiency | ||||
| Inventory Turnover | 2.31 | 2.18 | 2.66 | 2.75 |
| Cash Conversion Cycle | 159.96 | 161.16 | 130.54 | 121.87 |